Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden

Ruth Etzioni, Lorelei Mucci, Shu Chen, Jan Erik Johansson, Katja Fall, Hans Olov Adami

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: The number of patients in Sweden treated with radical prostatectomy for localized prostate cancer has increased exponentially. The extent to which this increase reflects treatment of nonlethal disease detected through prostate-specific antigen (PSA) screening is unknown. Experimental Design: We undertook a nationwide study of all 18,837 patients with prostate cancer treated with radical prostatectomy in Sweden from 1988 to 2008 with complete follow-up through 2009. We compared cumulative incidence curves, fit Cox regression and cure models, and conducted a simulation study to determine changes in treatment of nonlethal cancer, in cancer-specific survival over time, and effect of lead-time due to PSA screening. Results: The annual number of radical prostatectomies increased 25-fold during the study period. The 5-year cancer-specific mortality rate decreased from 3.9% [95% confidence interval (CI), 2.5-5.3] among patients diagnosed between 1988 and 1992 to 0.7% (95% CI, 0.4-1.1) among those diagnosed between 1998 and 2002 (Ptrend < 0.001). According to the cure model, the risk of not being cured declined by 13% (95% CI, 12%-14%) with each calendar year. The simulation study indicated that only about half of the improvement in disease-specific survival could be accounted for by lead-time. Conclusion: Patients overdiagnosed with nonlethal prostate cancer appear to account for a substantial and growing part of the dramatic increase in radical prostatectomies in Sweden, but increasing survival rates are likely also due to true reductions in the risk of disease-specific death over time. Because the magnitude of harm and costs due to overtreatment can be considerable, identification of men who likely benefit from radical prostatectomy is urgently needed.

Original languageEnglish (US)
Pages (from-to)6742-6747
Number of pages6
JournalClinical Cancer Research
Volume18
Issue number24
DOIs
StatePublished - Dec 15 2012
Externally publishedYes

Fingerprint

Prostatectomy
Sweden
Prostatic Neoplasms
Confidence Intervals
Prostate-Specific Antigen
Neoplasms
Survival
Risk Reduction Behavior
Research Design
Survival Rate
Costs and Cost Analysis
Mortality
Incidence
Therapeutics
Medical Overuse

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Etzioni, R., Mucci, L., Chen, S., Johansson, J. E., Fall, K., & Adami, H. O. (2012). Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. Clinical Cancer Research, 18(24), 6742-6747. https://doi.org/10.1158/1078-0432.CCR-12-1537

Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. / Etzioni, Ruth; Mucci, Lorelei; Chen, Shu; Johansson, Jan Erik; Fall, Katja; Adami, Hans Olov.

In: Clinical Cancer Research, Vol. 18, No. 24, 15.12.2012, p. 6742-6747.

Research output: Contribution to journalArticle

Etzioni, R, Mucci, L, Chen, S, Johansson, JE, Fall, K & Adami, HO 2012, 'Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden', Clinical Cancer Research, vol. 18, no. 24, pp. 6742-6747. https://doi.org/10.1158/1078-0432.CCR-12-1537
Etzioni, Ruth ; Mucci, Lorelei ; Chen, Shu ; Johansson, Jan Erik ; Fall, Katja ; Adami, Hans Olov. / Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. In: Clinical Cancer Research. 2012 ; Vol. 18, No. 24. pp. 6742-6747.
@article{46e2d0d56198476e97348898b4eb8191,
title = "Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden",
abstract = "Purpose: The number of patients in Sweden treated with radical prostatectomy for localized prostate cancer has increased exponentially. The extent to which this increase reflects treatment of nonlethal disease detected through prostate-specific antigen (PSA) screening is unknown. Experimental Design: We undertook a nationwide study of all 18,837 patients with prostate cancer treated with radical prostatectomy in Sweden from 1988 to 2008 with complete follow-up through 2009. We compared cumulative incidence curves, fit Cox regression and cure models, and conducted a simulation study to determine changes in treatment of nonlethal cancer, in cancer-specific survival over time, and effect of lead-time due to PSA screening. Results: The annual number of radical prostatectomies increased 25-fold during the study period. The 5-year cancer-specific mortality rate decreased from 3.9{\%} [95{\%} confidence interval (CI), 2.5-5.3] among patients diagnosed between 1988 and 1992 to 0.7{\%} (95{\%} CI, 0.4-1.1) among those diagnosed between 1998 and 2002 (Ptrend < 0.001). According to the cure model, the risk of not being cured declined by 13{\%} (95{\%} CI, 12{\%}-14{\%}) with each calendar year. The simulation study indicated that only about half of the improvement in disease-specific survival could be accounted for by lead-time. Conclusion: Patients overdiagnosed with nonlethal prostate cancer appear to account for a substantial and growing part of the dramatic increase in radical prostatectomies in Sweden, but increasing survival rates are likely also due to true reductions in the risk of disease-specific death over time. Because the magnitude of harm and costs due to overtreatment can be considerable, identification of men who likely benefit from radical prostatectomy is urgently needed.",
author = "Ruth Etzioni and Lorelei Mucci and Shu Chen and Johansson, {Jan Erik} and Katja Fall and Adami, {Hans Olov}",
year = "2012",
month = "12",
day = "15",
doi = "10.1158/1078-0432.CCR-12-1537",
language = "English (US)",
volume = "18",
pages = "6742--6747",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden

AU - Etzioni, Ruth

AU - Mucci, Lorelei

AU - Chen, Shu

AU - Johansson, Jan Erik

AU - Fall, Katja

AU - Adami, Hans Olov

PY - 2012/12/15

Y1 - 2012/12/15

N2 - Purpose: The number of patients in Sweden treated with radical prostatectomy for localized prostate cancer has increased exponentially. The extent to which this increase reflects treatment of nonlethal disease detected through prostate-specific antigen (PSA) screening is unknown. Experimental Design: We undertook a nationwide study of all 18,837 patients with prostate cancer treated with radical prostatectomy in Sweden from 1988 to 2008 with complete follow-up through 2009. We compared cumulative incidence curves, fit Cox regression and cure models, and conducted a simulation study to determine changes in treatment of nonlethal cancer, in cancer-specific survival over time, and effect of lead-time due to PSA screening. Results: The annual number of radical prostatectomies increased 25-fold during the study period. The 5-year cancer-specific mortality rate decreased from 3.9% [95% confidence interval (CI), 2.5-5.3] among patients diagnosed between 1988 and 1992 to 0.7% (95% CI, 0.4-1.1) among those diagnosed between 1998 and 2002 (Ptrend < 0.001). According to the cure model, the risk of not being cured declined by 13% (95% CI, 12%-14%) with each calendar year. The simulation study indicated that only about half of the improvement in disease-specific survival could be accounted for by lead-time. Conclusion: Patients overdiagnosed with nonlethal prostate cancer appear to account for a substantial and growing part of the dramatic increase in radical prostatectomies in Sweden, but increasing survival rates are likely also due to true reductions in the risk of disease-specific death over time. Because the magnitude of harm and costs due to overtreatment can be considerable, identification of men who likely benefit from radical prostatectomy is urgently needed.

AB - Purpose: The number of patients in Sweden treated with radical prostatectomy for localized prostate cancer has increased exponentially. The extent to which this increase reflects treatment of nonlethal disease detected through prostate-specific antigen (PSA) screening is unknown. Experimental Design: We undertook a nationwide study of all 18,837 patients with prostate cancer treated with radical prostatectomy in Sweden from 1988 to 2008 with complete follow-up through 2009. We compared cumulative incidence curves, fit Cox regression and cure models, and conducted a simulation study to determine changes in treatment of nonlethal cancer, in cancer-specific survival over time, and effect of lead-time due to PSA screening. Results: The annual number of radical prostatectomies increased 25-fold during the study period. The 5-year cancer-specific mortality rate decreased from 3.9% [95% confidence interval (CI), 2.5-5.3] among patients diagnosed between 1988 and 1992 to 0.7% (95% CI, 0.4-1.1) among those diagnosed between 1998 and 2002 (Ptrend < 0.001). According to the cure model, the risk of not being cured declined by 13% (95% CI, 12%-14%) with each calendar year. The simulation study indicated that only about half of the improvement in disease-specific survival could be accounted for by lead-time. Conclusion: Patients overdiagnosed with nonlethal prostate cancer appear to account for a substantial and growing part of the dramatic increase in radical prostatectomies in Sweden, but increasing survival rates are likely also due to true reductions in the risk of disease-specific death over time. Because the magnitude of harm and costs due to overtreatment can be considerable, identification of men who likely benefit from radical prostatectomy is urgently needed.

UR - http://www.scopus.com/inward/record.url?scp=84871224268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871224268&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-1537

DO - 10.1158/1078-0432.CCR-12-1537

M3 - Article

VL - 18

SP - 6742

EP - 6747

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 24

ER -